Assisted Reproduction Safety and Risks

Congenital malformations among babies born following letrozole or clomiphene for infertility treatment

Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S, Chakravarty BN

PloS one, 9(10), e108219, 2014
DOI 10.1371/journal.pone.0108219 PMID 25272289 PMC PMC4182712

RRM Academy Synopsis

Birth defect rates were similar with letrozole, clomiphene or no drug

A study of 623 babies born to women with infertility found birth defect rates were similar after letrozole, clomiphene or no drug. Rates were 2.5 percent with letrozole, 3.9 percent with clomiphene and 2.9 percent with no drug. The differences were not significant.

Key Findings

  • Malformations or chromosomal abnormalities occurred in 5 of 171 babies (2.9%) conceived without treatment, 5 of 201 (2.5%) after letrozole and 10 of 251 (3.9%) after clomiphene.
  • The overall prevalence of congenital malformations did not differ significantly among the three groups (P<0.648).
  • Hypospadias occurred in 3 of 251 babies (1.2%) after clomiphene and in none of the babies in the other two groups.
  • Singleton birth weight was significantly lower after clomiphene than after letrozole (p<0.02).

Interpretation

The authors ran the study because earlier reports linked letrozole with more malformations, and India suspended its use for infertility in October 2011. Letrozole rates fell in the same range as clomiphene and natural conception, and the authors say the undue fear against letrozole may be uncalled for. It is a retrospective cohort from one tertiary infertility center of babies born from January 2007 to December 2011 to women aged 21 to 35. Staff gathered outcomes from medical files and parent phone calls. Pediatricians examined babies with a suspected anomaly. The authors call for a large multicenter prospective trial.

RRM Context

Restorative reproductive medicine looks for the reason ovulation is irregular or absent. When a drug is used to induce ovulation, its record for the children born afterward is part of the evidence clinicians weigh. This cohort adds one data point on that record.

Abstract

Context

Clomiphene citrate (CC) is the first line drug for ovulation induction but because of its peripheral antiestrogenic effect, letrozole was introduced as the 2nd line drug. It lacks the peripheral antiestrogenic effect and is associated with similar or even higher pregnancy rates. Since letrozole is a drug for breast cancer, its use for the purpose of ovulation induction became controversial in the light of studies indicating an increased incidence of congenital malformations.

Aims

To evaluate and compare the incidence of congenital malformations among offsprings of infertile couples who conceived naturally or with clomiphene citrate or letrozole treatment.

Design and Setting

A retrospective cohort study done at a tertiary infertility centre.

Materials and Methods

A total of 623 children born to infertile women who conceived naturally or following clomiphene citrate or letrozole treatment were included in this study. Subjects were sorted out from medical files of both mother and newborn and follow up study was done based on the information provided by parents through telephonic conversations. Babies with suspected anomaly were called and examined by specialists for the presence of major and minor congenital malformations. Other outcomes like multiple pregnancy rate and birth weight were also studied.

Results

Overall, congenital malformations, chromosomal abnormalities were found in 5 out of 171 (2.9%) babies in natural conception group and 5 out of 201 babies in the letrozole group (2.5%) and in 10 of 251 babies in the CC group (3.9%).

Conclusions

There was no significant difference in the overall rate of congenital malformations among children born to mothers who conceived naturally or after letrozole or CC treatment.

Key Messages

Congenital malformations have been found to be comparable following natural conception, letrozole and clomiphene citrate. Thus, the undue fear against letrozole may be uncalled for.

Topics

By this author

Related research

Assisted Reproduction › Safety and Risks › Birth Defects · Therapeutics › Ovulation Agents › Aromatase Inhibitors · Pregnancy › Neonatal Outcomes › Neonatal Morbidity
Sunita Sharma, Sanghamitra Ghosh, Soma Singh, Astha Chakravarty, Ashalatha Ganesh, Shweta Rajani
S Sharma, S Ghosh, S Singh, A Chakravarty, A Ganesh, S Rajani
PMID 25272289 25272289 DOI 10.1371/journal.pone.0108219 10.1371/journal.pone.0108219 Sharma et al. 2014, Sharma 2014